Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mark Fesen (NPI 1639149545)

Field	Value
Entity Type	Individual
Organization	Mark Fesen
Address	204 Cleveland St
City	Great Bend
State	KS
ZIP	67530
Taxonomy	Medical Oncology Physician
NPI Enumerated	January 24, 2006

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider’s lifetime billing footprint is effectively single‑payer: total Medicare revenue is $1.5M and there is no Medicaid billing on file, indicating the practice’s reimbursements are driven entirely by Medicare. The NPI was enumerated on 2006-01-24 (~20 years ago), which supports a long-tenured clinical presence in the market.

Revenue is highly concentrated in a small set of injectable therapies: the precomputed top‑3 Medicare codes account for 61.7% of the provider’s total Medicare revenue. The three highest-revenue codes are J9271 (35.5% of Medicare revenue), J1569 (17.1%), and J0897 (9.1%), which together dominate the revenue mix and suggest drug administration is the primary revenue driver.

The CPT/HCPCS mix is consistent with a medical oncology/infusion practice: high-revenue biologic and immunotherapy codes such as J9271 (pembrolizumab) and J1569 (immune globulin) are paired with chemotherapy administration codes (96413, 96365, 96367, G0498) and supportive agents (J1454, J0881, J1437). This combination points to onsite infusion services and chemotherapy management as core offerings, with evidence of both initial infusions and subsequent/add-on administrations.

Competitive standing varies by code: J9271 ranks #967 of 1841 (47th percentile) and is described as typical/unremarkable volume nationally, while J1569 ranks #108 of 542 (80th percentile) and J0897 ranks #1807 of 10057 (82th percentile), both above typical national volume. In other words, the provider is a modest-to-strong participant for some high-revenue drugs rather than a dominant national leader across its full portfolio.

Several specific codes are statistical outliers in national comparisons, indicating unusually high relative activity for those services: 99213 is labeled an extreme outlier (rank #1629 of 457151, 100th percentile) and 96372 is also an extreme outlier (rank #339 of 58224, 99th percentile). J1454 is another extreme outlier (rank #3 of 422, 100th percentile), which—combined with high visit volume—suggests elevated procedural throughput and frequent use of certain antiemetic/infusion agents.

Operationally, some average paid amounts and claim volumes underscore where costs concentrate: J9271 shows 11.8K claims at $43 avg paid/claim for $507.4K revenue, while J1454, though only 221 claims, has a $352 avg paid/claim contributing $77.8K in revenue. These patterns indicate that both high‑volume lower‑unit‑price infusions and lower‑volume higher‑unit‑price agents materially affect the practice’s Medicare receipts, and they are likely to be focal points for utilization review or contracting.

Multiple infusion and administration codes sit at or above the 95th percentile (for example 96365 at the 95th, 96367 at the 98th, G0498 at the 97th, and 96413 at the 95th percentile), signaling above-typical intensity of infusion services relative to national peers. That concentration of administration activity suggests the practice operates as a high-throughput infusion center, which has implications for resource planning, staffing, and supply costs.

The absence of any Medicaid billing on file, paired with a Medicare revenue profile dominated by oncology and infusion codes, implies a payer-concentrated business model focused on Medicare beneficiaries receiving complex injectable therapies. For payer or network analysts, this profile suggests negotiations and utilization management efforts should prioritize oncology drug handling, infusion workflows, and the handful of codes that generate the majority of Medicare revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,800	$40	$507.4K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,780	$40	$244.1K
J0897	Injection, denosumab, 1 mg	7,200	$20	$129.6K
J1437	Injection, ferric derisomaltose, 10 mg	7,300	$20	$124.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,650	$60	$102K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	220	$350	$77.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	620	$90	$57.6K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	15,950	$1	$31.9K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	500	$50	$23K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	600	$30	$19.2K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Mark Fesen — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	16	20	28,900	$40	$1.1M
J1569	2	10	6,320	$40	$195.9K
J1568	12	10	3,690	$30	$129K
J0897	26	180	2,160	$20	$81.5K
J1437	1	10	2,050	$20	$48.2K
J0881	4	10	10,830	$1	$33.8K
J1454	1	10	90	$350	$31.7K
96413	15	80	80	$90	$26.3K
99214	3,017	4,310	120	$70	$16.4K
G0498	3	20	90	$110	$10.9K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mark Fesen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Mark Fesen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rosewood Services, Inc.	KS	Home Health Agency	$0	$55.5M
Sunflower Diversified Services	KS	Developmentally Disabled Services Day Training Agency	$0	$29M
Rescare Kansas, Inc.	KS	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$15.4M
Center For Counseling And Consultation	KS	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$11.6M
Center For Counseling And Consultation	KS	Community/Behavioral Health Agency	$0	$6.4M
Great Bend Childrens Clinic PA	KS	Rural Health Clinic/Center	$0	$4.4M
Heart Of Kansas Family Health Care, Inc.	KS	Federally Qualified Health Center (FQHC)	$0	$3M
Ukhs Great Bend, LLC	KS	Rural Health Clinic/Center	$0	$2.6M
Ukhs Great Bend, LLC	KS	Rural Health Clinic/Center	$0	$2.6M
Ukhs Great Bend, LLC	KS	Rural Health Clinic/Center	$0	$2.5M

Mark Fesen — Billing Profile & Reimbursement Data

Sign up for Mark Fesen — Billing Profile & Reimbursement Data policy alerts

Mark Fesen — Billing Profile & Reimbursement Data

Sign up for Mark Fesen — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References